Summit Therapeutics PLC (SMMT) is a Healthcare · Biotechnology company listed on NASDAQ. Price $17.85 (+0.73%), Market cap $14.48B, 52-week low–high $13.85 ~ $29.32.
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. I
Financial statements, price targets, institutional (13F) holdings and related news for Summit Therapeutics PLC are updated in real time on BlackAll Trade.
Summit Therapeutics PLC trades at $17.85 (+0.73%). Real-time quotes and charts are available on BlackAll Trade.
Summit Therapeutics PLC has a market cap of about $14.48B.
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead de